Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II

BACKGROUND AND AIMS: Ontamalimab, a fully-human monoclonal antibody targeting MAdCAM-1, induced remission in patients with moderate-to-severe ulcerative colitis [UC] in the TURANDOT study. We aimed to assess long-term safety, tolerability, and efficacy of ontamalimab in TURANDOT II. METHODS: TURANDO...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Crohns Colitis
Autori principali: Reinisch, Walter, Sandborn, William J, Danese, Silvio, Hébuterne, Xavier, Kłopocka, Maria, Tarabar, Dino, Vaňásek, Tomáš, Greguš, Miloš, Hellstern, Paul A, Kim, Joo Sung, Sparrow, Miles P, Gorelick, Kenneth J, Hoy, Michael, Goetsch, Martina, Bliss, Caleb, Gupta, Charu, Cataldi, Fabio, Vermeire, Séverine
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2021
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8218706/
https://ncbi.nlm.nih.gov/pubmed/33599720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ecco-jcc/jjab023
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi